Clinical trials: Cystic Fibrosis Lung
Cystic Fibrosis
Phase II Study of Digitoxin to Treat Cystic Fibrosis
This study will measure the inflammatory effects of digitoxin on IL-8 and neutrophil counts in induced sputum in stable Cystic Fibrosis (CF) patients and the pharmacokinetics of digitoxin in serum. Funding Source-FDA OOPD
- Trial name
- NCT00782288
- Testing
- digitoxin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Jewish Health
Lung Infection
Detecting Lung Infections Through Vibration
The purpose of this study is to test a lung air vibrator device for vibrating air inside the lung. This exploratory diagnostic trial will test a novel and non-invasive means of detecting lower airway infections using exhaled…
- Trial name
- NCT02056860
- Testing
- Group 1 will receive 15 Hz, Group 2 will receive 30 Hz, Group 3 will receive 60 Hz
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Florida
Cystic Fibrosis, Mucoviscidosis
Assessment of Quadriceps Muscle Electrostimulation Used in Patients Suffering From Cystic Fibrosis
This is an add-on, randomized, open label, clinical trial that evaluates the use of quadriceps electrostimulation as an additional retraining procedure in patients suffering from cystic fibrosis.
- Trial name
- STIMUCO (NCT00391703)
- Testing
- Electrostimulation programme: using a cycloergometer, Usual sport activity
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Grenoble
Cystic Fibrosis
PEP and O-PEP Device for Nebulization in Cystic Fibrosis
Physiotherapy is an essential element in the comprehensive treatment of patients with cystic fibrosis. In symptomatic individuals, from a respiratory system perspective, it should be performed regularly, as it directly…
- Trial name
- NCT06964074
- Testing
- Nebulization with OPEP device, Nebulization with PEP device, Nebulization with Pari LC Sprint
- Where
- 2 sites in Poland
- Volunteers
- 70 people
- Sponsor
- National Institute for Tuberculosis and Lung Diseases, Poland
Cystic Fibrosis
Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis
OBJECTIVES: I. Assess the safety and efficacy of gene transfer into the nasal epithelium using Ad5-CB-CFTR, an E1-deleted adenovirus vector containing the cystic fibrosis transmembrane conductance regulator gene, in patients with…
- Trial name
- NCT00004779
- Testing
- Ad5-CB-CFTR
- Volunteers
- 12 people
- Sponsor
- National Center for Research Resources (NCRR)
Cystic Fibrosis, Cystic Fibrosis Gastrointestinal Disease
Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs
This is a Phase 2 study sponsored by AzurRx SAS and involves testing of a new medication for the compensation of exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis (CF).
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Gastrointestinal Disease, Cystic Fibrosis of Pancreas
- Trial name
- NCT04302662
- Testing
- MS1819-SD
- Where
- 10 sites in Hungary, Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- AzurRx SAS
Cystic Fibrosis
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
The purpose of this study is to evaluate the safety of long-term ivacaftor treatment in participants with cystic fibrosis (CF) from Studies 110 (NCT01614457), 111 (NCT01614470), and 113 (NCT01685801).
- Trial name
- KONTINUE (NCT01707290)
- Testing
- Ivacaftor
- Where
- 38 sites in United States, Belgium and 2 more
- Volunteers
- 125 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis
To determine the relative bioavailability of the capsule (reference) and tablet (test) formulations of FDL169 in healthy adult males and females, and to evaluate the pharmacokinetic (PK) profile FDL169 tablets (test formulation)…
- Trial name
- NCT02767297
- Testing
- FDL169
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Flatley Discovery Lab LLC
Cystic Fibrosis
Thoracic Mobility in Cystic Fibrosis Care
Cystic fibrosis (CF) is an inherited, genetic disease of the body's mucus-producing glands that primarily affects the lungs and gastrointestinal tract.
- Trial name
- NCT04696198
- Testing
- Manual Therapy Intervention, Standard care
- Where
- Sweden
- Volunteers
- 63 people
- Sponsor
- Göteborg University
Cystic Fibrosis, Lung Diseases
Gene Modifiers of Cystic Fibrosis Lung Disease
The purpose of this study is to examine genetic modifiers of the severity of cystic fibrosis lung disease.
- Trial name
- NCT00037765
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- University of North Carolina, Chapel Hill
Cystic Fibrosis
A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
The objectives of the study are to demonstrate that Tobrineb®/Actitob®/Bramitob® is non-inferior to TOBI® in the primary efficacy variable, forced expiratory volume in one second (FEV1) percent of predicted normal, and to compare…
- Trial name
- CT03 Core (NCT00885365)
- Testing
- tobramycin / Bramitob, tobramycin / TOBI
- Where
- 44 sites in Czechia, France and 6 more
- Volunteers
- 324 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Cystic Fibrosis, Portal Hypertension
Portal Hypertension and Systemic Endothelial Function
Cystic fibrosis can affect organs other than the lungs. Liver disease affects about 30% of patients: its main manifestation is the development of portal hypertension (PHT).
- Trial name
- ENDOTH-MUCO (NCT02850692)
- Testing
- measure of endothelial function, Blood sample, Hepatic elastography
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hopital Foch
Cystic Fibrosis
PEP and OPEP Devices in Cystic Fibrosis
Cystic fibrosis (CF) is the most common severe autosomal recessive genetic disease in Caucasians. The CFTR (cystic fibrosis transmembrane regulator) gene, which encodes the chloride channel of the epithelial cell membrane, is…
- Trial name
- NCT05801952
- Testing
- Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- National Institute for Tuberculosis and Lung Diseases, Poland
Cystic Fibrosis
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
- Trial name
- STAR-TER (NCT03489629)
- Testing
- Trimethoprim Sulfamethoxazole (TMP/SMX), Minocycline, Mupirocin
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of North Carolina, Chapel Hill
Cystic Fibrosis
BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects
The objective of this study is to investigate the safety, tolerability, and pharmacokinetics of BI 443651 in male and female healthy volunteers and subjects with Cystic Fibrosis (CF).
- Trial name
- NCT02976519
- Testing
- BI 443651
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
YOGA-CF (Yoga Outcomes Get Assessed in Cystic Fibrosis)
The goal of this clinical trial is to investigate the effects of yoga participation for adults with cystic fibrosis. The main question it aims to answer is: does participation in yoga affect health-related quality of life for…
- Trial name
- YOGA-CF (NCT06120465)
- Testing
- Yoga
- Where
- United Kingdom
- Volunteers
- 314 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cystic Fibrosis
Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis
Respiratory und intestinal microbiome will bei analyzed during a period of 6 months. In a retrospective analysis it will be looked for correlations between microbiome and cf therapy (e.g.
- Trial name
- NCT03335202
- Testing
- analysis of microbiome
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- University of Kiel
Cystic Fibrosis
Anti-IL5 and Other Biotherapies in Cystic Fibrosis
Our project is to describe retrospectively and prospectively CF patients treated with biotherapy in French CF centers. Main objective: To describe the clinical and paraclinical course of CF patients before and after treatment…
- Trial name
- MAB-CF (NCT04256772)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Lung and Heart-lung Transplantation
Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation
The purpose of this study is to evaluate in lung or heart-lung transplant patients on tacrolimus and mycophenolate the impact of optimized mofetil (MMF) therapeutic drug monitoring and dose adjustment of both drugs on the…
- Trial name
- BASALT (NCT00975663)
- Testing
- Tacrolimus and MMF
- Where
- 9 sites in Belgium, France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Limoges
Cystic Fibrosis (CF), CFTR Gene Mutation
Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy
In cystic fibrosis (CF) renal base excretion is impaired, due to mutations in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene, since CFTR function is crucial in regulation of the kidney's HCO3- excretion.
- Trial name
- NCT05818319
- Testing
- 12 hours ETI pause, 36 hours ETI pause, 60 hours ETI pause
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus